New Drug Application News and Research

RSS
FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Mylan releases generic version of Felbatol Tablets in U.S.

Mylan releases generic version of Felbatol Tablets in U.S.

Mylan announces U.S. launch of generic Ortho Tri-Cyclen Lo Tablets

Mylan announces U.S. launch of generic Ortho Tri-Cyclen Lo Tablets

First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

Amarantus seeks FDA's Rare Pediatric Disease Designation and ODD to treat GCMN with Engineered Skin Substitute

Amarantus seeks FDA's Rare Pediatric Disease Designation and ODD to treat GCMN with Engineered Skin Substitute

Mylan announces launch of Linezolid Tablets, 600 mg in U.S.

Mylan announces launch of Linezolid Tablets, 600 mg in U.S.

FDA approves non-alcoholic Docetaxel Injection

FDA approves non-alcoholic Docetaxel Injection

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

EMA CHMP considers AcelRx's ARX-04 for acute pain treatment for centralized review

EMA CHMP considers AcelRx's ARX-04 for acute pain treatment for centralized review

CSL submits rIX-FP new drug application to Japan's Pharmaceuticals and Medical Devices Agency

CSL submits rIX-FP new drug application to Japan's Pharmaceuticals and Medical Devices Agency

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

Soligenix reports positive results from SGX942 Phase 2 trial in patients with head and neck cancer

TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan

TaiGen releases Taigexyn (nemonoxacin) capsules in Taiwan

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Kitov Pharmaceuticals' KIT-302 drug candidate meets primary efficacy endpoint in Phase III clinical trial

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection

FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection

FDA grants Fast Track status to Cardiorentis' Ularitide for treatment of ADHF

FDA grants Fast Track status to Cardiorentis' Ularitide for treatment of ADHF

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma